TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

被引：0

作者：

D. Ferraro

D. Goldstein

R. L. O’Connell

J. R. Zalcberg

K. M. Sjoquist

N. C. Tebbutt

P. Grimison

S. McLachlan

L. L. Lipton

P. Vasey

V. J. Gebski

C. Aiken

M. Cronk

S. Ng

C. S. Karapetis

J. Shannon

机构：

[1] University of Sydney,National Health and Medical Research Council Clinical Trials Centre

[2] University of New South Wales,Prince of Wales Clinical School

[3] Monash University,Department of Epidemiology and Preventive Medicine

[4] Austin Health,Haematology and Oncology Clinics of Australasia

[5] Chris O’Brien Lifehouse,Department of Medical Oncology

[6] St Vincents Hospital,Department of Pathology

[7] University of Melbourne,undefined

[8] Western Health,undefined

[9] Wesley Medical Centre,undefined

[10] Nambour General Hospital,undefined

[11] Flinders University,undefined

[12] Nepean Cancer Care Centre,undefined

[13] University of Melbourne,undefined

[14] Sir Charles Gairdner Hospital,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2016年 / 78卷

关键词：

Biliary tract cancer; KRAS; Panitumumab; Chemotherapy; Phase II trial; Cancer antigen 19.9;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：361 / 367

页数：6

共 188 条

[11] Sant M(1989)Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1-10
[12] Trama A(1996)A note on quantifying follow-up in studies of failure time Control Clin Trials 17 343-346
[13] Faivre J(2002)Quantification of the completeness of follow-up Lancet 359 1309-1310
[14] Valle J(2014)Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial Lancet Oncol 15 819-828
[15] Wasan H(2014)BINGO: targeted therapy for advanced biliary-tract cancer Lancet Oncol 15 778-780
[16] Palmer DH(2015)A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer Ann Oncol 26 943-949
[17] Cunningham D(2014)Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials Ann Oncol 26 13-21
[18] Anthoney A(2013)Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis Int J Cancer 133 1914-1925
[19] Maraveyas A(undefined)undefined undefined undefined undefined-undefined
[20] Madhusudan S(undefined)undefined undefined undefined undefined-undefined